[ News ] [ Our People ] [ Awards ]
[ Management Team ] [ Scientific Advisors ] [ Board of Directors ]
Erich Mohr, Ph.D., R.Psych.
Chairman & Chief Executive Officer
Founder of MedGenesis Therapeutix Inc.
Erich Mohr, Ph.D., R.Psych, is the Chairman and CEO of MedGenesis Therapeutix Inc. which he founded in 2005. Dr. Mohr, a Professor of Medicine and Psychology at the University of Ottawa until 1997
has over 23 years of experience in experimental therapeutics of CNS disorders. He is credited with over 150 publications, books, book chapters and abstracts and has edited the Handbook of Clinical
Trials: The neurobehavioral approach. Dr. Mohr has chaired and/or served on several regulatory advisory panels for the approval of new products for the treatment of neurodegenerative disease and is
the former Chairman and Chief Executive Officer of CroMedica Global Inc. (which merged with PRA International in 2002 to form one of the top 5 contract research organizations in the world) and the
co-founder of several biotechnology companies. His most recent position was with PRA International, where he served as Chief Scientific Officer. Over the course of his career, Dr. Mohr has overseen and/or participated in dozens of clinical development programs resulting in a number of approved drugs.
H. Christian Fibiger, Ph.D.
Chief Scientific Officer
H. Christian Fibiger, Ph.D. received his B.Sc. in Chemistry and Psychology
from the University of Victoria in 1966 and his Ph.D. in Psychopharmacology from
Princeton University in 1970. Dr. Fibiger was formerly Senior Vice President and
Chief Scientific Officer for Biovail Laboratories International (2008-2010).
From 2003 until 2007 he was Vice President and Global Head of Neuroscience at
Amgen. In this position he was responsible for Amgen's worldwide Neuroscience
discovery efforts ranging from early exploratory research through clinical
candidate selection. Before joining Amgen in 2003, Dr. Fibiger served as Vice
President of Neuroscience Discovery Research and Clinical Investigation, and LRL
Europe at Eli Lilly and Company. Prior to moving to Lilly in 1998, Dr. Fibiger
was Professor and Head of the Division of Neurological Sciences and Chair of the
University Graduate Program in Neuroscience at the University of British
Columbia in Vancouver. He has made numerous contributions to neuroscience
research and, during his academic career, was among the top 100 most cited
scientists in neuroscience. He has received many honors for his research
contributions, including the Clark Institute Prize in Psychiatry, the Heinz
Lehmann Award of the Canadian College of Neuropsychopharmacology, the Killam
Research Prize, the Gold Medal in Health Sciences from the Science Council of
British Columbia and the Tanenbaum Distinguished Scientist Award in
Schizophrenia Research. He is a Fellow of the American College of
Neuropsychopharmacology (ACNP). Dr. Fibiger has served on the editorial boards
of leading neuroscience journals and has been coeditor of
Neuropsychopharmacology, the official publication of the ACNP. He is currently a
Board member of a number of neuroscience focussed biotechnology companies, Chief
Scientific Officer, HLS Therapeutics Inc., and Assistant Dean, Research, Faculty
of Medicine, University of British Columbia.
Greg A. Johnson
President and Chief Financial Officer
Mr. Johnson has 24 years of clinical research experience, and is a recognized expert in electronic data capture and the implementation and use of computerized systems in a clinical research setting. Before joining MedGenesis, Mr. Johnson held several senior positions at PRA International including Vice President, Operations for the Americas, and Vice President, Global Data Management. During his tenure at PRA International, he was responsible for the successful management of dozens of global clinical programs in several therapeutic areas. In addition to his expertise in clinical data management, Mr. Johnson has wide-ranging experience in strategic planning, project management and operations management. Mr. Johnson has an M.Sc. in Clinical Research, holds Project Management Professional (PMP) certification, and is a Fellow in the Institute of Clinical Research (FICR).
Lara Longpre, M.Sc., MBA
Chief Operating Officer
Ms. Longpre re-joined MedGenesis in October 2014 as Chief Operating Officer. She brings to MedGenesis more than 23 years of experience developing innovative and complex therapies, most recently at Jennerex Biotherapeutics
where as Chief Operating Officer. As COO, she was responsible for program
management for the lead product, alliance management across 3 international
collaboration partners, clinical operations for over 11 clinical trials,
technical operations, regulatory affairs, and quality assurance. Prior to
Jennerex, Ms. Longpre was Senior Vice-President, Clinical & Corporate Affairs at
MedGenesis where she was responsible for business operations including the
intellectual property portfolio, corporate files, and clinical development plans
and budgets. Ms. Longpre continued to serve as a consultant to MedGenesis during
her tenure at Jennerex. Ms. Longpre previously held several senior positions
with PRA International/CroMedica including operations, regulatory affairs, and
proposals & contracts. She holds a B.A. in Biology from Cornell University, an M.Sc. from Harvard Medical School and an MBA from Queen's University.
Matthias Luz, M.D.
Chief Medical Officer
Dr. Luz is a board-certified anesthesiologist and intensive care physician with an extensive background in epidemiology, clinical trial methodology and global regulatory affairs. In addition to
years of clinical experience, Dr. Luz has 24 years of global product development experience in the biopharmaceutical and clinical research industry. Before joining MedGenesis
in 2006, Dr. Luz was the Vice President and Head, Global Product Development Services for PRA International. In this capacity, Dr. Luz led an
accomplished team of senior physician-scientists and drug development experts involved in the design and implementation of high quality development programs from pre-IND to Phase III and submission. During a previous tenure at Behringwerke/Hoechst Marion Roussel/Aventis, Dr. Luz led the team that brought Refludan®, the first therapeutic for heparin-induced thrombocytopenia, to market worldwide. Dr. Luz also held other senior positions at Knoll/Abbott and Cardion.